By Fineline Cube 
Boehringer Ingelheim (BI), a German pharmaceutical leader, has entered into a strategic collaboration and global licensing agreement with Tessellate Bio, a Netherlands-based biotech firm. The partnership aims to co-develop first-in-class oral precision therapies targeting cancers that rely on Alternative Lengthening of Telomeres (ALT) mechanisms. This innovative approach targets approximately 15% of solid tumors, including osteosarcoma and glioblastoma.
Partnership and Financial Terms
Under the agreement, Tessellate Bio is set to receive upfront license fees, research funding, and technical milestone payments, with the potential for additional success-based milestones. The total deal value could exceed EUR 500 million (USD 567 million), reflecting BI’s commitment to advancing this novel therapeutic approach.
Tessellate Bio’s Technology
Tessellate Bio brings to the collaboration its proprietary small-molecule inhibitors, which target a undisclosed molecular pathway critical for the proliferation of ALT-positive cancer cells. This pathway is a hallmark of several aggressive solid tumors, and its targeting represents a significant advancement in the field of oncology.-Fineline Info & Tech